Dear Editor,Pancreatic ductal adenocarcinoma(PDAC)remains a significant health problem with an increase in the incidence and a five-year survival rate of only 10%[1].The Phosphoinositide 3-kinase-protein kinase-B-mech...Dear Editor,Pancreatic ductal adenocarcinoma(PDAC)remains a significant health problem with an increase in the incidence and a five-year survival rate of only 10%[1].The Phosphoinositide 3-kinase-protein kinase-B-mechanistic target of rapamycin(PI3K-AKT-mTOR)pathway is a driver pathway in PDAC and an important therapeutic target[2].We[3]and others[4–6]have demonstrated that the mTOR kinase is a therapeutic target in PDAC,and rationally designed mTOR inhibitor(mTORi)-based combination therapies are emerging[2].展开更多
基金FUNDING STATEMENT This work was supported by the Deutsche Forschungsgemeinschaft(DFG):SFB824 C9 to D.S.and G.S.SCHN 959/3-2 to G.S.+6 种基金SFB1321(Project-ID 329628492)P13 to G.S.SFB1321(Project-ID 329628492)P11 to D.S and M.S.R.SFB1321 S01 and S02 to G.S.,M.R.,D.S.,and R.RSCHN 959/6-1 to G.S.RE 3723/4-1 to M.R.,SFB1361(Project-ID ID 393547839)to O.H.KDFG KR2291-9-1/12-1/14-1 to O.H.K.,Wilhelm-Sander-Stiftung(2017.048.2 toG.S.and 2019.086.1 to G.S.and O.H.K.)Deutsche Krebshilfe(70113760 toG.S.,Max Eder Program 111273 to M.R.)and Brigitte und Dr.Konstanze Wegener-Stiftung(Projekt 65)to O.H.K.This research project/publication was funded by LMU Munich's Institutional Strategy LMU excellent within the framework of the German Excellence Initiative to M.S.R.
文摘Dear Editor,Pancreatic ductal adenocarcinoma(PDAC)remains a significant health problem with an increase in the incidence and a five-year survival rate of only 10%[1].The Phosphoinositide 3-kinase-protein kinase-B-mechanistic target of rapamycin(PI3K-AKT-mTOR)pathway is a driver pathway in PDAC and an important therapeutic target[2].We[3]and others[4–6]have demonstrated that the mTOR kinase is a therapeutic target in PDAC,and rationally designed mTOR inhibitor(mTORi)-based combination therapies are emerging[2].
